Expression of E-cadherin and N-cadherin in Epithelial-to-Mesenchymal Transition of Osteosarcoma: A Systematic Review.

Autor:	Issagholian L; Medical School, California University of Science and Medicine, Colton, USA., Tabaie E; Medical School, California Northstate University College of Medicine, Elk Grove, USA., Reddy AJ; Ophthalmology, California University of Science and Medicine, Colton, USA., Ghauri MS; Neurosurgery, California University of Science and Medicine, Colton, USA., Patel R; Internal Medicine, East Tennessee State University Quillen College of Medicine, Johnson City, USA.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2023 Nov 27; Vol. 15 (11), pp. e49521. Date of Electronic Publication: 2023 Nov 27 (Print Publication: 2023).
DOI:	10.7759/cureus.49521
Abstrakt:	Osteosarcoma (OS) is a debilitating cancer of the bone that commonly afflicts the young and old. This may be de novo or associated with tumorigenic syndromes. However, many molecular mechanisms are still being uncovered and may offer greater avenues for screening and therapy. Cadherins, including E-cadherin and N-cadherin/vimentin, are involved in epithelial-to-mesenchymal transmission (EMT), which is key for tumor invasion. A study reviewing the relationship between OS and cadherins might elucidate a potential target for therapy and screening. A robust literature review was conducted by searching PubMed with the keywords "osteosarcoma", "cadherin", "e-cadherin" and "n-cadherin". Of a preliminary 266 papers, 25 were included in the final review. Review articles and those without primary data were excluded. Loss of E-cadherin is noted in metastatic cell lines of osteosarcoma. Overexpression of E-cadherin or knockout of N-cadherin/vimentin results in loss of metastatic potential. There are several methods of gene knockout, including CRISPR-Cas9 gene editing, viral vector insertion with micro RNA complementary to long noncoding RNA within gene segments, or proteomic editing. Screening for EMT and genetic treatment of EMT is a possible avenue for the treatment of refractory osteosarcoma. Several studies were conducted ex vivo. Further testing involving in vitro therapy is necessary to validate these methods. Limitations of this study involve a lack of in vivo trials to validate methods. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2023, Issagholian et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu